Gene therapies have been the subject of tremendous scientific research and investment. With hundreds of clinical trials in progress and
Continue Reading The Evolving Gene Editing Landscape: From Research Tool to Market
Gene therapies have been the subject of tremendous scientific research and investment. With hundreds of clinical trials in progress and…
Continue Reading The Evolving Gene Editing Landscape: From Research Tool to MarketOn February 28, 2022, the Patent Trial and Appeal Board (PTAB) issued a decision in Interference No. 106,115, which granted…
Continue Reading PTAB Sides with Broad in Patent Dispute over CRISPR Gene Editing of Eukaryotic Cells
Vertex Pharmaceuticals and Mammoth Biosciences, a Brisbane, California-based genetic research company, announced a new collaboration for the development of in …
Continue Reading Vertex and Mammoth Biosciences Ink $700M Deal for Ultra-Small CRISPR Systems
Caribou Biosciences, Inc., a Berkeley, California-based CRISPR genome-editing biopharmaceutical company, raised $304M in an initial public offering, one of the…
Continue Reading Caribou Biosciences Raises $304M in Potentially the Largest Gene Editing IPO
On July 13, 2021, Prime Medicine, a Massachusetts biotech company developing next generation gene editing technology, emerged from stealth mode…
Continue Reading Prime Medicine Emerges with $315 Million to Develop Next Generation Gene Editing Platform
We use cookies to enhance your user experience. By continuing to use this site you are giving your consent for us to use cookies. For more information, please see our Privacy Policy.